Tagged with M

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…

Biogen Idec Germany Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The growth potential of the biotech industry is incomparable to any other sector in the pharmaceutical industry, and the entire industry…

Dr. F. Köhler Chemie Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community. What have been the main challenges you faced when taking over the company 25 years ago and becoming its General…

Hikma Pharma One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the Hikma organisation, and how important are Hikma’s German operations for the company today? Hikma first established operations in Germany in…

Biomax Informatics Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company and how successful have you been so far in achieving your aims? When I founded the company 10 years ago,…

GlaxoSmithKline Given the heated debate over NHS reform and the new revised bill proposed by the government, what are you current priorities as President of the ABPI and how have these evolved since you stepped into that role in April 2010? The ABPI represents the R&D and innovation-based pharmaceutical companies in…

IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…

DKFZ - German Cancer Research Center The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for the HPV vaccine. What were the set of values and visions that allowed the DKEZ to have such a prominent…

Argentine Ministry of Science ¿Porque fue creado en Ministerio de Ciencia y Tecnología, con que visión? Muchos países están aportando importancia a la ciencia y tecnología y representa la razón del desarrollo económico y social de esos mismos países. El ministerio en Argentina se creó en ese sentido, para ayudar a transformar el conocimiento…

Baxter Germany Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you took the reigns of the German operations? Baxter Germany has grown steadily in the German market primarily thanks to its…

Ministry of Health Indonesia Overall health indicators have improved significantly in Indonesia in recent years. However, the country still faces many challenges and there are many areas in need of further improvement. What is your assessment on how government policy is contributing toward improved health care in terms of current policies and priorities? Indonesia’s…